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Structured Abstract: Objective: To emphasize the importance of troponin in the context of a new score for risk stratifying 
acute coronary syndromes (ACS) patients. Although troponins have powerful prognostic value, current ACS scores do not 
fully capitalize this prognostic ability. Here, we weigh troponin status in a multiplicative manner to develop the TRACS 
score from previously published Rush score risk factors (RRF).  
Methods: 2,866 ACS patients (46.7% troponin positive) from 9 centers comprising the TRACS registry, were randomly 
split into derivation (n=1,422) and validation (n=1,444) cohorts. In the derivation sample, RRF sum was multiplied by 3 if 
troponins were positive to yield the TRACS score, which was grouped into five categories of 0-2, 3-5, 6-8, 9-11, 12-15 
(multiples of 3). Predictive performance of this score to predict hospital death was ascertained in the validation sample.  
Results: The TRACS score had ROC AUC of 0.71 in the validation cohort. Logistic regression, Kaplan-Meier analysis, 
likelihood-ratio and Bayesian Information Criterion (BIC) test indicated that weighing troponin status with 3 in the 
TRACS score improved the prediction of mortality. Hosmer-Lemeshow test indicated sound model fit.  
Conclusions: We demonstrate that weighing troponin as a multiple of 3 yields robust prognostication of hospital mortality 
in ACS patients, when used in the context of the TRACS score. 
Key Words: Acute coronary syndrome, Troponin biomarkers, Risk stratification, Prognosis, TRACS score, RUSH score,   
Receiver operating characteristic curve.  
INTRODUCTION 
  The ACC/AHA guidelines recommend accurate risk 
stratification of chest pain patients for initiating evidence-
based therapies in the management of acute coronary   
syndromes (ACS) [1]. Risk stratification is achieved by   
using the various published risk scores and by clinical   
assessment. Troponin biomarkers represent an important   
part of the clinical assessment. They are widely used and   
are powerful prognostic predictors of adverse events in   
ACS syndromes. However, current risk stratification   
models like the Thrombolysis in Myocardial Infarction 
(TIMI) score, which though is simple to use may underesti-
mate the predictive ability of powerful predictors like   
troponin biomarkers [2-4]. Accurate risk stratification is   
particularly important when stronger risk factor variables 
like troponin are present, but weaker ones are absent to give 
a low or intermediate score.  
  Another example of a risk prediction model in ACS is the 
Rush score [5-7]. It has a sound pathophysiologic basis that 
originates from Braunwald’s unstable angina classification 
[5-7]. The Rush score, developed from registry data, is a 
regression-weight based, validated instrument predicting   
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mortality in ACS patients, but does not use troponin status 
[5-7]. In contrast, troponin biomarkers form an important 
component of most risk stratification models like the TIMI 
[8] and Global Registry of Acute Coronary Events (GRACE) 
[9] risk models. 
  We sought to increase the predictive performance of the 
Rush risk score, by first exploring the relationship between 
the Rush risk factors and troponin biomarkers and then   
incorporating troponin into the Rush risk factors as an   
additional component of this score. The rationale for select-
ing the Rush score for modification was that it is consists of 
easily ascertainable risk factors, is simple to use and it is one 
of the few scores that still do not use troponin. We use The 
Registry of Acute Coronary Syndromes (TRACS registry) 
for model development and validation.  
METHODS 
Study Population 
  The Registry of Acute Coronary Syndromes (TRACS) 
consists of patients presenting with ACS to 9 participating 
hospitals, including tertiary medical centers and community 
hospitals. Consecutive patients meeting the predefined   
criteria for ACS based on the International Classification of 
Disease (ICD) code (410.X) and who were seen in the   
emergency department at these centers for evaluation of 
chest pain between April 1, 1999, and December 31, 2000, 
were enrolled in TRACS (n=3,468 patients). All data were 40    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Amin et al. 
retrieved by a retrospective chart audit that was supervised 
by a designated physician at the participating center. Patients 
with the ICD code (410.X) criteria for ACS underwent EKG 
evaluation and three serial blood draws for cardiac biomark-
ers. After arrival in the ED, the mean time(s) elapsed until 
the first troponin was 5.7 hours, the second troponin was 
11.8 hours and third troponin was18.6 hours respectively. A 
positive troponin was defined as a troponin value above the 
reference range at the participating center. For participating 
centers this included a value of > 0.5 ng/ml for the troponin I 
assay, and  0.02 ng/ml when the troponin T assay was used. 
The TRACS dataset did not include the magnitude of the 
troponin level, but only a dichotomous variable of troponin 
status. All participating hospitals received approval for this 
study from their institutional review boards.  
  The TRACS database included 602 patients with ST   
elevation MI. These were excluded and the resulting 2,866 
patients were split randomly into two samples – a derivation 
sample (n= 1422, 49.6%) and a validation sample (n = 1444, 
50.4%) using the random function STATA command   
“sample” which draws random samples from the data.   
Random sampling here was defined as drawing observations 
without replacement. 
  We used the derivation sample for developing the 
TRACS score by modifying the previously published Rush 
score [5]. The Rush score is a regression-based score derived 
from the original Braunwald classification of unstable angina 
and hence does not use troponin as a risk factor [5,10]. It has 
a sound pathophysiologic basis and has been prospectively 
validated [7]. It consists of (scores in parenthesis): (1) MI  
in the past 14 days (score 6), (2) not using  blockers as an 
outpatient medication (score 4), (3) ST depression (score 3), 
(4) ongoing chest pain (score 2), (5) diabetes (score 2), and 
(6) age (score 2 if age >75 years; score 1 if age <65-75 
years). The sum of these scores determines the Rush score. 
We modified it to develop the TRACS score as follows:  
  First, the TRACS score only assigns a single point to the 
above variables that results in a simple sum of Rush risk 
factors (RRF sum) (not regression weights; this strategy is 
identical to that of the TIMI score). Secondly, we incorpo-
rated troponin elevation to the RRF sum in a multiplicative 
(rather than additive) manner as follows: It is well   
established that troponin elevation adds independent value to 
risk stratification [11-13]. This assumption was confirmed 
here with a logistic regression model where the dependent 
variable was hospital mortality and the two independent   
variables were troponin elevation (OR 2.88, p = 0.007) and 
the RRF sum (OR 1.46, p = 0.047). The weight of troponin 
elevation was rounded up to 3 (from 2.88) and multiplied 
with the RRF sum to yield the TRACS score: 
TRACS Score = Sum of Rush Score Variables 3  
(if Troponin Positive) 
  In troponin negative patients, only the RRF sum was 
used. The TRACS score ranged from 0-15 and had an   
exponential distribution (Fig. 1) because of the above   
multiplicative function. For simplicity of use, the TRACS 
score was grouped into five categories of scores of 0-2, 3-5, 
6-8, 9-11 and 12-15. This categorization was based on   
dividing patients by a multiple of three. As seen here, each 
category score is roughly double the previous category and 
this is consistent with the exponential nature of the TRACS 
score (which occurs due to multiplication by 3).  
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Distribution of the TRACS score and observed mortality 
by the TRACS score categories in the validation cohort. 
  TRACS score category 1 (score 0-2) represented patients 
who were troponin negative and had 1-2 Rush score risk 
factors, TRACS score category 2 (score 3-5) had both   
troponin positive (with only1 Rush risk factor) and negative 
patients (with 3-5 Rush risk factors) while TRACS score 
categories 3 (score 6-8), 4 (score (9-11) and 5 (score 12-15) 
represented the troponin positive patients with 2, 3 and 4-5 
Rush score risk factors, respectively (Table 1). Thus the 
TRACS score does not consider troponin as a ‘risk factor’, 
but moves up its importance as an entirely separate domain 
in risk stratification. Troponin positive patients get higher 
TRACS score ranks, via  application of a multiplicative   
function of 3 to incorporate the robust prognostic value of 
troponin into the Rush score variables.  
  Some generalizations were made while calculating these 
scores. All patients by inclusion criteria had chest pain on 
admission and were coded to have ‘ongoing chest pain’. For 
the TRACS score patients  65 years of age were assigned 
one point, while the original Rush score gives 1 point for 
patients between 65-75 years and 2 points for patients  75 
years. None of the patients had all 6 Rush score risk factors 
in this dataset. 
Statistical Analyses 
  The data are presented as frequency or mean ± SD.   
Characteristics were compared across groups with 
2 tests   
for categorical variables and t tests for continuous variables. 
The outcome was hospital death. 
  For testing the validity of the TRACS score, the method 
of split-sample validation was used. We randomly split   
the 2,688 patients into a derivation sample and a validation 
sample. The predictive performance of the TRACS score 
was ascertained in the validation sample as follows: The 
prognostic ability of the TRACS score was measured   
and compared with the c-statistic representing the area   
under the receiver operating characteristic (ROC) curves 
(AUC) for prediction of hospital death. A c-statistic > 0.70 
was considered to have good discriminatory ability. ROC 
analyses were also done across various sub-groups of   
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patients, to see if the score was robust in any particular   
sub-groups. Multivariable logistic regression was used to 
predict death from other covariates including the TRACS 
score. Model calibration of the TRACS score was tested   
with the Hosmer and Lemeshow goodness-of-fit test and   
by plotting the observed versus expected mortality in the 
subgroups of TRACS score [14]. Likelihood-ratio testing 
was performed to ascertain the contribution of the troponin 
in the TRACS score over and beyond the Rush risk factors, 
towards prediction of hospital mortality. The Bayesian   
counterpart of this - the Bayesian Information Criterion (BIC) 
difference methodology - that overcomes the drawbacks   
of likelihood-ratio testing was also used. BIC was developed 
by Schwartz [15] and modified by Raftery [16]. The BIC 
difference methodology uses the BIC of two nested models 
to estimate the BIC difference and then evaluates which 
model would be more likely (the “true” model) - before   
or after dropping one of the explanatory variables (here   
the TRACS score). The BIC difference is a rigorous test   
of comparison between the likelihood of two models: the 
original model and the model without one of the variables 
and ascertains whether the "true" model contains the variable 
in question. 
  Finally, Kaplan Meier survival analyses and Cox propor-
tional hazards regression were used to analyze survival in  
the TRACS score categories as a function of time. Hospital 
stay in days was the time variable, while in-hospital death 
was the failure event. The log rank test was used to test   
the equality of survival distributions. Stata version 8.2   
(StataCorp, College Station, TX) was used to analyze the data. 
RESULTS 
  Baseline characteristics of the TRACS registry popula-
tion across the derivation and validation cohorts is shown   
in Table 3. The population mostly comprised of elderly, 
white, male patients with a high prevalence of diabetes, 
known CAD and hyperlipidemia, who were high risk, mostly 
non-ST segment myocardial infarction (NSTEMI) and   
unstable angina patients. There were no major differences 
between the randomly split derivation and validation cohorts 
(Table 3). 
  Of the total 2,866 patients, troponin biomarkers were 
positive in 1,339 (46.7%) patients, who were classified as 
having a NSTEMI. Of these NSTEMI patients, 950 (33.2%) 
patients had a first positive troponin on arrival in the   
emergency department, while the remainder 389 (13.6%) 
patients initially were troponin negative, but subsequently on 
repeat testing 6 hours and 12 hours apart, turned positive. 
The troponin negative patients (n= 1,527, 53.3%) were   
classified as having unstable angina. Of the 2,866 patients, 
the primary end-point of hospital mortality occurred in 75 
(2.62 %) patients. The mean number of Rush risk factors 
were 2.24 ± 0.89 in the entire sample. Table 2 displays the 
in-hospital mortality by troponin status and sum of Rush risk 
factors in the derivation cohort. 
 Fig.  (1) shows the distribution of the TRACS score and 
deaths (%) in each score sub-groups in the validation sample. 
A steep increase in mortality was seen with increase in 
TRACS score category. The TRACS score showed a good 
discriminatory ability for predicting in-hospital mortality. 
Table 1.  Frequency Distribution (%) of the Sum of Rush Risk Factor Variables by Troponin Status in the Derivation Cohort 
  Troponin Negative  Troponin Positive 
Rush Risk Factors  1 2 3 4 5  1  2  3  4  5 
TRACS Score Categories                 
Score 0-2  164  328              
Score 3-5     186  56 3  144        
Score 6-8          2 8 1          
Score 9-11            206       
Score 12-15              49  5 
 
Table 2.  In-Hospital Mortality by Troponin Status and Sum of Rush Risk Factors in the Derivation Cohort 
Rush Score Risk Factors Sum  Troponin Negative pts  Troponin Positive pts  Total 
  N  Death (%)  N  Death (%)   
1  164 0.61  143 0  307 
2  328 1.83  281  3.56  609 
3  186 1.08  206  5.34  392 
4  56 0  49  6.12  105 
5  3 0  5  0  8 
Total 737  1.22  684  3.51  1,421 42    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Amin et al. 
Table 3.  Study Characteristics of Patients in the Derivation and Validation Cohorts of the TRACS Registry 
  Derivation Cohort  Validation Cohort  Total  P value 
 N  Percent  N  Percent     
Demographics and Risk Factors 
Mean age  66.9±13.5    67.0±13.5       
Male gender  848  60  861  60  1709  0.937 
Diabetes 437  31  440  30  877  0.880 
Known history of CAD  712  50  713  49  1425  0.710 
Family history  262  18  261  18  523  0.808 
Hypercholesterolemia 879  62  883  61  1762  0.715 
Past myocardial infarction > 2 weeks  420  30  383  27  803  0.073 
Recent myocardial infarction  2 weeks  
(re-infarction or post-infarct angina) 
63 4  65  5  128  0.927 
Race           0.305 
Asian 4  0  2  0  6   
Black 121  9  149  10  270   
Caucasian 1170  82  1159  80  2329   
Hispanic 48  3  37  3  85   
Race not available  6  0  5  0  11   
Not abstracted  35  2  38  3  73   
Others 38  3  52  3  90   
Risk Stratification and Acuity of Presentation Variables 
Unstable angina  737  52  790  55  1527  0.122 
Non-STEMI 685  48  654  45  1339  0.122 
Mean TIMI score  3.7 ± 1.1    3.7 ± 1.1      0.685 
TIMI score risk factors distribution            0.511 
1 32  2  36  2  68   
2 171  12  185  13  356   
3 434  31  407  28  841   
4 443  31  490  34  933   
5 266  19  256  18  522   
6 70  5  61  4  131   
7 6  0  9  1  15   
Mean Rush score risk factors sum  2.2 ± 2.1    2.3 ± 2.2      0.147 
Distribution of Rush score risk factors sum            0.666 
1 308  22  290  20  598   
2 609  43  611  42  1220   
3 392  28  415  29  807   
4 105  7  116  8  221   
5 8  1  12  1  20   
Mean TRACS score (raw score)  4.4 ± 3.0    4.4 ± 3.1      0.818 
Mean TRACS score categories (1 to 5)  3.8 ± 3.6    3.7 ± 3.6      0.724 
Distribution of TRACS score categories            0.702 
TRACS category 1:     0-2  492  35  507  35  999   
TRACS category 1:     3-5  389  27  409  28  798   
TRACS category 1:     6-8  281  20  268  19  549   
TRACS category 1:     9-11  206  14  195  14  401   
TRACS category 1:     12-15  54  4  65  5  119   Troponin Biomarkers and ACS Risk Stratification  The Open Cardiovascular Medicine Journal, 2009, Volume 3    43 
Table 3…..Coutd 
  Derivation Cohort  Validation Cohort  Total  P value 
 N  Percent  N  Percent     
Troponin Variables 
First troponin positive 486  34  464 32  950  0.130 
Second troponin positive 572  40  545 38  1117  0.276 
Third troponin positive 514  36  464 32  978  0.069 
Any troponin positive 685  48  654 45  1339  0.122 
EKG Variables 
EKG LBBB  69  5  56  4  125  0.202 
EKG non-specific ST-T abnormalities 50  4  52  4  102  0.902 
EKG LVH  34  2  33  2  67  0.851 
EKG ST depression  192  14  255  18  447  0.002 
Any EKG Abnormality 351  25  350 24  701  0.782 
Outcome 
In-hospital mortality  33  2.3  42  2.9  75  0.320 
 
ROC analysis demonstrated that area under the curve (AUC) 
was 0.7123 (95% CI 0.62-0.79) (Fig. 2). This was a   
significant improvement over the ROC AUC of the sum of 
Rush risk factors alone (AUC 0.6517, 95% CI 0.60-0.70). 
ROC analyses also showed a high predictive ability of   
the TRACS score in the sub-groups of diabetes, age 65, 
those with CAD, and troponin positivity (Table 4). We also 
calculated the TIMI score as described previously [8]. When 
ROC analyses were repeated for the predictive ability of the 
TRACS score across the traditional categories of TIMI 
score: low risk (TIMI score 0-3), intermediate risk (TIMI 
score 4-5) and high risk (TIMI score 6-7), the TRACS score 
had good discriminatory ability across all three traditional 
TIMI risk groups. It was reasonably good in the intermediate 
risk category of the TIMI score; an area where the clinician 
faces the most difficulty in risk stratification, and use of a 
separate score here shows statistical evidence of good   
predictive performance.  
  By univariate logistic regression analyses, the TRACS 
score categories were strongly predictive of death (OR per 
incremental category (0 to 5) was 1.24, 95%CI 1.14 – 1.34, p 
value <0.001). Hosmer and Lemeshow goodness-of-fit 
2 
was 2.53 and a p-value of 0.47, for five distinct quantile 
groups of the estimated probability of hospital mortality. 
This indicated a sound model fit. This model calibration is 
shown in Fig. (3). The TRACS score demonstrated little 
variation between the observed and expected prediction of 
death across its five score categories. 
  By multivariate analyses, the TRACS score independ-
ently predicted mortality (OR 1.14 per incremental category, 
95% CI 1.01-1.28) even when adjusted for other known and 
well-documented, life-saving therapy covariates like revas-
cularization, aspirin, beta blockers, heparin, and glycoprotein 
IIb/IIIa inhibitor use pre-cath and in the cathlab (Table 5). 
The Rush score risk factor sum was an important covariate 
of this model, and the TRACS score independently predicted  
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Receiver operating characteristic (ROC) curve for the 
TRACS score in the validation cohort. 
mortality over and beyond that predicted by the RRF sum. 
Likelihood-ratio tests (LRT) between pairs of maximum 
likelihood logistic models were also performed to see if 
TRACS score had independent prognostic value. LRT was 
used to compare hierarchically nested models: the above full 
model shown in Table 5 and then a second nested model that 
dropped the TRACS score. This comparison resulted in a 
LRT 
2 value = 4.91, p = 0.0267, indicating that the TRACS 
score was a powerful and independent predictor of   
in-hospital death. Since the full model included RRF sum  
as one of the model covariates, the above LRT result also 
implies that troponin status incorporated into the TRACS 
score with a weight of 3, contributes significantly, over and 
beyond the RRF sum, in the prediction of hospital mortality. 
A Bayesian approach to model comparison employing the 
use of the Bayesian Information Criterion (BIC) difference 
test revealed even better results. The BIC difference uses the 
Bayesian Information Criterion to estimate the probability 
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that the model would be more likely after dropping one of 
the explanatory variables. Using the full model in Table 5, 
when each explanatory variable was dropped from the full 
model and BIC differences between the reduced (nested) 
model and the full (original) models were estimated for each 
of the explanatory variables in the full model, only the 
TRACS score had the largest BIC difference of 7.3, and BIC 
prime of 9.4 (p= 0.026). A BIC difference of 6-10 is consid-
ered “strong evidence” for variable selection according   
to Raftery [16]. Thus, troponin status with a weight of 3   
incorporated in the TRACS score conveyed the highest   
information content in the prediction of hospital mortality, 
when directly compared with any other factor in the model. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Model Calibration of both TRACS score in the validation 
cohort. 
  Finally, Kaplan Meier survival analysis demonstrated 
that increasing TRACS score was associated with an increas-
ing rate of mortality as a function of hospital stay (time). 
Fig. (4) shows that the Kaplan Meier curves for different 
score categories separated early and remained separate   
(log rank p<0.0001). Cox proportional hazards regression 
yielded a hazard ratio of 1.2 (p< 0.001, 95% CI 1.1 – 1.3) per 
incremental score category of the TRACS score. 
  These analyses suggest that using troponin status in a 
multiplicative manner with a weight of 3 adds incremental 
value in risk stratification for the prediction of hospital   
mortality, when used to improve the Rush score. 
  Similar exploratory analyses using the TIMI score [8] 
were also performed, although this was not the primary   
objective of this paper. When the TIMI risk score was   
recalculated using troponin in a multiplicative function with 
a weight of 4 (as determined via logistic regression model) 
this modified TIMI risk score had an ROC AUC of 0.6550 
that was also a significant improvement over the original 
TIMI risk score (ROC AUC 0.5452, p value for difference  
= 0.0003).  
DISCUSSION 
  Our data suggest that troponin status bears a multiplica-
tive relationship to in-hospital mortality in risk stratification 
of ACS patients. We derive and validate this relationship to 
be a multiplicative factor of 3. The resulting TRACS score 
using this relationship can better risk-stratify an unselected, 
ED patient population presenting with chest pain, independ-
ent of that provided by the Rush score.  
  Using troponin status in such a multiplicative manner 
creates an exponential model of risk (Fig. 1) that closely 
approximates risk in real-world scenarios, where truly   
independent risk factors acting together multiply, rather than 
add risk. This creates a better separation of the risk profile in 
the intermediate zone, and consequently improved risk 
prediction. A potential downfall of such a strategy is to 
create widely differing and unstable estimates of risk across 
categories of the score. The Hosmer-Lemeshow 
2 statistic, a 
measure of model stability and goodness-of-fit, does not 
demonstrate this. We hypothesize that this exponential   
risk modeling is a major reason for better risk prediction. In 
contrast, risk scores that assign a weight of 1 to troponin 
elevation, lose a major part of the prognostic information 
contained in troponin and is a reductive approach to the   
superior prognostic value of troponin. 
  Multiple large cohort and randomized studies also   
demonstrate that troponin is extremely important for   
 
Table 4.  Predictive Performance of the TRACS Score in Clinically Relevant Patient Subgroups in the Validation Cohort 
Subgroup  N  ROC AUC  95% CI 
Diabetes  439  0.7573  0.63 - 0.88 
Age  65  850  0.6585  0.56 - 0.75 
Male  859  0.7265  0.60 - 0.86 
Female  552  0.7110  0.60 - 0.82 
Troponin positive pts  653  0.7137  0.64 - 0.79 
Pts with known CAD or past MI  980  0.7518  0.64 - 0.87 
EKG ischemia (ST depression)  255  0.7161  0.59 - 0.84 
By TIMI Score Category Subgroups 
 Low TIMI score (1-3)  625  0.6912  0.53 – 0.85 
 Intermediate TIMI score (4-5)  745  0.6732  0.55 – 0.79 
 High TIMI score (6-7)  70  0.7268  0.56 – 0.89 
Linear Regression Line Equation
y = 0.97x + 0.001
R
2 = 0.9573
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prognostication. Recently a meta-analysis of 7 randomized 
trials and 11 cohort studies involving more than 10,000   
patients, found that serum troponin had a three- to eightfold 
higher short-term risk of death for ACS patients [17].   
Our data, showing a 3-fold risk is consistent with the   
meta-analysis data [17]. Thus, a greater emphasis on the   
information contained in troponin elevation for clinical   
decision making is a highlight of the TRACS score. 
 
 
 
 
Fig. (4). Kaplan Meier survival analysis for the TRACS score. 
  Other potential reasons account for the increased   
predictive ability of the TRACS score: 
  The TRACS score is a registry derived score, in compari-
son to other scores like the TIMI score that are derived and 
validated in clinical trial data. Non-participants in trials have 
a higher risk of adverse outcomes and greater heterogeneity 
than participants. Hence, it has been suggested that scoring 
systems be derived from observational data [4,18]. Our 
analysis from TRACS registry supports this observation. The 
strong discriminatory performance and superior calibration 
of the TRACS score indicate that it is likely to be useful in a 
“real-world” ACS population. Other studies done in the 
community reflect these observations. A community study 
demonstrated that AUC of the TIMI score was low for 
NSTEMI patients (c-statistic 0.59) [4]. Another community-
based study comparing the TIMI, PURSUIT and GRACE 
scores identified that the TIMI score presented the lowest 
accuracy of the three risk scores (AUC 0.585) [2]. In this 
same study the GRACE score, derived from registry data, 
presented the best discriminatory accuracy, which was offset 
by its complexity that required the use of a computer   
program to calculate it. A Canadian registry of ACS patients 
[19] demonstrated that the GRACE score, derived from a 
less selected population compared to the PURSUIT score, 
provided superior calibration. These authors underscored the 
importance of risk model validation in the general ACS 
population rather than a clinical trial population to establish 
its generalizability before integration into clinical practice. 
This is consistent with our findings also. A meta-analysis of 
trials and cohort studies looking at the prognostic value of 
troponin, found that the magnitude of risk associated with a 
positive troponin was greater in cohort studies of consecutive 
patients than in clinical trials [17]. This again emphasizes 
that highly selected trial patients differ from unselected,   
heterogeneous, consecutive patients from cohort studies   
who have a greater potential for variation in underlying 
prognosis. 
Study Limitations 
  This study suffers from several limitations. Firstly,   
generalizations made in calculating the sum of Rush risk 
factors and consequently the TRACS score (coding severe 
angina for example) may have resulted in an upward skew in 
the risk scores. This may have curtailed the discriminatory 
Table 5.  Multivariable Logistic Regression Analysis Incorporating TRACS Score in the Validation Cohort 
Variables  Odds Ratio  P value  95% CI 
Score Variables 
Rush risk factors sum  0.65  0.52  0.18 - 2.41 
TRACS score (per incremental point 0 to 5)  1.14  0.03  1.01 - 1.28 
Risk Factor Variables 
Age  65  4.30  0.07  0.88 - 20.96 
Male gender  0.92  0.81  0.47 - 1.79 
Diabetes  1.16  0.84  0.27 - 5.03 
Hypercholesterolemia  1.27  0.50  0.63 - 2.54 
EKG Ischemia (ST depression)  3.04  0.11  0.78 - 11.88 
Therapy Variables 
Aspirin use  0.38  0.01  0.18 - 0.81 
Heparin use  1.53  0.35  0.63 - 3.73 
Glycoprotein IIb/IIIa antagonist use  0.75  0.55  0.30 - 1.91 
Beta blocker use  0.37  0.18  0.09 - 1.59 
Nitroglycer in use  0.22  0.00  0.11 - 0.44 
Revascularization (PCI or CABG)  0.44  0.06  0.19 - 1.02 
Logrank test P value = 0.0003
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range of the risk score in the low range but is unlikely to 
have altered the overall pattern of risk observed in this study. 
Sensitivity analyses conducted with and without inclusion of 
the chest pain variable in the RRF and the TRACS scores, 
did not change the predictive performance of either of these 
scores. Similarly, the variable of angiographic stenosis used 
in the TIMI score, was modified in this analysis to include 
any documented history of MI or known CAD. The TIMI 
risk score as applied in PRISM-PLUS study also used a   
similar strategy and supports the expansion to include   
historical information that may be more widely available 
than angiographic data alone. As discussed in the original 
report of the TIMI score, it was anticipated that it might   
undergo some refinement during future application to facili-
tate wider clinical use [8].  
  A second major limitation of this data is that the magni-
tude of troponin release was not available in the TRACS 
dataset and no effort was made to estimate mortality risks by 
increasing magnitude of troponin release, while previous 
data have demonstrated increased mortality with higher   
troponin levels [20]. At worst, including troponin as only a 
dichotomous variable underestimates the prognostic ability 
of troponin (due to misclassification bias) and drives   
the odds ratio towards null. Despite this, we were able to 
demonstrate good prognostic ability of troponin in the   
context of the TRACS score. Generally, however, when   
using any risk score, it is also easier to use a single ‘yes/no’, 
dichotomous variable for troponin status and provides   
simplicity of use. 
  Another limitation of this study is of differences in   
end-points. Most risk scores use composite end-points like 
death and re-infarction and target vessel revascularization.   
In the TRACS registry information on re-infarction and   
urgent target vessel revascularization was not available. 
However, it is generally agreed that death is a robust and 
preferable end-point to measure [21, 22]. The main purpose 
of this paper is to show the incremental prognostic value   
of troponin in risk stratification and we were able to demon-
strate that with the TRACS score, despite only a small   
number of patients (2.68%) experiencing a hard outcome 
like death. This risk stratification may be extended in   
other datasets to include composite end-points. The weight 
of 3 that was identified for predicting mortality may not   
be applicable when using less conservative, composite   
end-points. 
  To conclude, the ideal score for risk stratification on   
admission for ACS should have a good balance between 
complexity and utility. The TRACS score, with its greater 
emphasis on troponin elevation used in a multiplicative   
manner is simple to use and provides an advantage over   
risk stratification. 
ABBREVIATIONS  
(ECG or EKG)  =  Electrocardiogram  
(ED)   =  Emergency department  
(MI)   =  Myocardial infarction  
(ACS)   =  Acute coronary syndrome  
(UA)   =  Unstable angina  
(NSTEMI)   =  Non-ST elevation acute coronary 
syndrome  
(CAD)   =  Coronary artery disease  
(TRACS)    =  The registry of acute coronary 
syndromes  
(TIMI)    =  Thrombolysis in myocardial 
infarction  
(ACC / AHA)   =  American college of cardiology / 
American heart association  
APPENDIX 
TRACS Hospital Sites 
  Cook County Hospital, Chicago, Illinois; Deaconess 
Hospital, Evansville, Indiana; East Texas Medical   
Center, Tyler, Texas; Lehigh Valley Hospital, Allentown, 
Pennsylvania; Mayo Clinic, Rochester, Minnesota;   
New Britain General Hospital, New Britain, Connecticut; 
Providence Yakima Medical Center, Yakima, Washington; 
Saint John Hospital, Detroit, Michigan; The Reading   
Hospital and Medical Center, West Reading, Pennsylvania. 
REFERENCES 
[1]    Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 
guideline update for the management of patients with unstable   
angina and non-ST-segment elevation myocardial infarction--
summary article: a report of the American College of Cardiol-
ogy/American Heart Association task force on practice guidelines 
(Committee on the Management of Patients With Unstable   
Angina). J Am Coll Cardiol 2002; 40: 1366-74. 
[2]    de Araujo GP, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI,   
PURSUIT, and GRACE risk scores: sustained prognostic value and 
interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 
26: 865-72. 
[3]   Ramsay G, Podogrodzka M, McClure C, Fox KA. Risk prediction 
in patients presenting with suspected cardiac pain: the GRACE and 
TIMI risk scores versus clinical evaluation. QJM 2007; 100: 11-8. 
[4]   Singh M, Reeder GS, Jacobsen SJ, Weston S, Killian J, Roger VL. 
Scores for post-myocardial infarction risk stratification in the 
community. Circulation 2002; 106: 2309-14. 
[5]   Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in 
unstable angina. Prospective validation of the Braunwald classifica-
tion. JAMA 1995; 273: 136-41. 
[6]   Calvin JE, Klein LW, VandenBerg BJ, Meyer P, Ramirez-Morgen 
LM, Parrillo JE. Clinical predictors easily obtained at presentation 
predict resource utilization in unstable angina. Am Heart J 1998; 
136: 373-81. 
[7]    Calvin JE, Klein LW, VandenBerg EJ, Meyer P, Parrillo JE.   
Validated risk stratification model accurately predicts low risk in 
patients with unstable angina. J Am Coll Cardiol 2000; 36: 1803-8. 
[8]   Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for 
unstable angina/non-ST elevation MI: A method for prognostica-
tion and therapeutic decision making. JAMA 200016; 284: 835-42. 
[9]   Bradshaw PJ, Ko DT, Newman AM, Donovan LR, Tu JV. Validity 
of the GRACE (Global Registry of Acute Coronary Events) acute 
coronary syndrome prediction model for six month post-discharge 
death in an independent data set. Heart 2006; 92: 905-9. 
[10]   Braunwald E. Unstable angina. A classification. Circulation 1989; 
80: 410-4. 
[11]   Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific 
troponin I levels to predict the risk of mortality in patients with 
acute coronary syndromes. N Engl J Med 1996; 335: 1342-9. 
[12]   Lindahl B, Venge P, Wallentin L. Relation between troponin T and 
the risk of subsequent cardiac events in unstable coronary artery 
disease. The FRISC study group. Circulation 1996; 93: 1651-7. 
[13]    Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac   
troponin T levels for risk stratification in acute myocardial   
ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335: 
1333-41. Troponin Biomarkers and ACS Risk Stratification  The Open Cardiovascular Medicine Journal, 2009, Volume 3    47 
[14]    Hosmer DW, Lemeshow S. Applied Logistic Regression. New 
York, NY. John Wiley & Sons 2000. 
[15]   Schwarz G. Estimating the dimension of a model. Ann Stat 1978; 
6: 461-4. 
[16]    Raftery A. Bayesian model selection in social research. Sociol 
Methodol 1995; 25: 111-96. 
[17]   Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go 
AS, Hlatky MA. The prognostic value of troponin in patients with 
non-ST elevation acute coronary syndromes: a meta-analysis. J Am 
Coll Cardiol 2001; 38: 478-85. 
[18]   Wong CK, White HD. Value of community-derived risk models  
for stratifying patients with non-ST elevation acute coronary   
syndromes. Eur Heart J 2005; 26: 851-2. 
[19]   Yan AT, Jong P, Yan RT, et al. Clinical trial-derived risk model 
may not generalize to real-world patients with acute coronary   
syndrome. Am Heart J 2004; 148: 1020-7. 
[20]    Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. 
Mechanisms behind the prognostic value of troponin T in unstable 
coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 
2001; 38: 979-86. 
[21]   Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems 
with use of composite end points in cardiovascular trials:   
systematic review of randomised controlled trials. BMJ 2007; 334: 
786. 
[22]   Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Compos-
ite outcomes in randomized trials: greater precision but with greater 
uncertainty? JAMA 2003; 289: 2554-9.  
 
 
Received: April 13, 2009  Revised: April 17, 2009  Accepted: April 22, 2009 
 
© Amin et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 